Avidity Biosciences Cash on Hand 2019-2022 | RNA
Avidity Biosciences cash on hand from 2019 to 2022. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Avidity Biosciences Annual Cash on Hand
(Millions of US $) |
| 2021 |
$406 |
| 2020 |
$328 |
| 2019 |
$95 |
| 2018 |
$ |
Avidity Biosciences Quarterly Cash on Hand
(Millions of US $) |
| 2022-03-31 |
$397 |
| 2021-12-31 |
$406 |
| 2021-09-30 |
$413 |
| 2021-06-30 |
$279 |
| 2021-03-31 |
$308 |
| 2020-12-31 |
$328 |
| 2020-09-30 |
$341 |
| 2020-06-30 |
$352 |
| 2020-03-31 |
|
| 2019-12-31 |
|
| 2019-09-30 |
|
| 2019-06-30 |
|
| 2018-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.728B |
$0.009B |
|
Avidity Biosciences Inc. is a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates(TM). The company's AOC platform design, engineer and develop therapeutics which combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies. Its lead product candidate consist AOC 1001, is designed to treat myotonic dystrophy type 1,and other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. Avidity Biosciences Inc. is based in SAN DIEGO.
|
